This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Gastrointestinal cancer

Stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117)

In vitro and mouse studies suggest an anti-KIT mAb could help treat gastrointestinal stromal tumors (GISTs). In Gleevec imatinib-resistant GIST cell lines, a mAb targeting KIT increased macrophage-mediated cancer cell phagocytosis and slowed growth compared with IgG. In mice bearing GIST xenografts, the anti-KIT mAb decreased tumor growth compared with IgG control. Next steps could include testing the antibodies in additional animal models.
Novartis AG's BCR-ABL tyrosine kinase inhibitor Gleevec is marketed to treat multiple cancers including GIST.
At least five companies have KIT inhibitors in preclinical and clinical testing to treat cancers.

SciBX 6(7); doi:10.1038/scibx.2013.159
Published online Feb. 21, 2013

Patent and licensing status unavailable

Edris, B. et al. Proc. Natl. Acad. Sci. USA; published online Feb. 4, 2013;
doi:10.1073/pnas.1222893110
Contact: Matt van de Rijn, Stanford University School of Medicine, Stanford, Calif.
e-mail:
mrijn@stanford.edu
Contact: Irving L. Weissman,
same affiliation as above
e-mail:
irv@stanford.edu